Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific, GMU, Johns Hopkins and Toronto’s UHN Extend Collaboration

Published: Wednesday, March 31, 2010
Last Updated: Wednesday, March 31, 2010
Bookmark and Share
Accelerating biomarker identification for cancer and other diseases may speed development of diagnostic tests that enable earlier disease detection.

Thermo Fisher Scientific Inc., has announced that its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has extended its groundbreaking collaboration with George Mason University’s Center for Applied Proteomics and Molecular Medicine (CAPMM), Johns Hopkins University and Toronto’s University Health Network (UHN).

For the past two years, these organizations have collaborated with BRIMS to accelerate the verification and validation of protein biomarkers for cancer and other diseases.

For years, biomarker researchers sought independent validation of putative biomarkers and routine, mass spectrometry-based quantitative assays suited for the rigors of clinical research.

Thermo Fisher’s BRIMS Center addressed these challenges by developing targeted SRM-based quantitative mass spectrometry workflows that enable rapid assay development and cross validation of biomarker assays across the network of laboratories. Each of the collaborators uses these biomarkers and assays as they perform research on identical Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer platforms.  

“Working together, the BRIMS Center and the collaborators demonstrated an instrument platform and an end-to-end workflow from sample preparation through data analysis that are easily and reproducibly transferred from laboratory to laboratory,” said Mary Lopez, director, BRIMS Center. “By continuing our work with these leading research groups, we can extend their ground-breaking research by continuing to apply the SRM-based workflow to previously validated clinical biomarkers.”

“Together, we’ve taken a remarkable step forward by combining the BRIMS Center’s expertise in workflow development, state-of-the-art Thermo Scientific technologies and the talent of leading researchers with valuable clinical expertise,” said Iain Mylchreest, vice president and general manager, life science mass spectrometry, Thermo Fisher Scientific. “By delivering reproducible, quantitative verification and validation of protein biomarkers in a clinical research setting, the researchers are now that much closer to their goal of developing tests for cancer.”

Members of the collaboration team presented their results, an inter-lab reproducibility study, at the U.S. Human Proteome Organization 2010 meeting, March 7-10, in Denver, Colorado.

The study is the first inter-lab study to demonstrate reproducible determination of protein abundance in a complex matrix such as blood. The study also demonstrated that an optimized biomarker assay can be implemented relatively quickly across several laboratories without need for additional optimization.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo, Children’s Hospital Los Angeles Partner
Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.
Friday, February 19, 2016
Thermo Fisher Scientific Receives IVDD CE Mark for LC-MS Products
Now available to clinical laboratories in Europe for general in vitro diagnostic use.
Friday, September 11, 2015
Ebola Sequencing Data Released to Global Research Community Online
To curb further spread of Ebola in Sierra Leone, a team of scientists that is part of an international, multi-organizational effort has released their first dataset of the virus’ genetic structure online.
Wednesday, June 03, 2015
Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo Scientific Announces Listing of the Ion PGM Dx System
Company has completed the listing with the U.S. FDA as class II medical device.
Saturday, September 20, 2014
Thermo Registers San Jose Facility with FDA
The site has established a quality system in accordance with the FDA Quality System Regulations to design and manufacture devices for analyzing samples from patients for in vitro diagnostic use.
Monday, June 16, 2014
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo Acquires Prionics AG
Thermo Fisher Scientific announce it has completed the acquisition of Prionics AG, a privately held animal health diagnostics company.
Monday, March 17, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
One Lambda Receives CE Mark Approval for C1qScreen
Assay cited in New England Journal of Medicine for use in determining impact on kidney graft survival.
Tuesday, November 19, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Scientific Enters into a Long-Term Agreement with Fujirebio
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.
Thursday, November 22, 2012
Thermo Fisher Scientific Completes Acquisition of One Lambda
The business will become part of Thermo Fisher’s Specialty Diagnostics Segment.
Friday, September 14, 2012
Thermo Scientific Ensures Patient Safety with Solution to Label and Track Tissue Samples in Pathology Laboratories
The new solutions include SlideMate on-demand slide printer and the PrintMate automated cassette printing system.
Thursday, April 22, 2010
Scientific News
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!